Referencia número: HY-112683

V-9302

34 Cited Publications

Revisión del cliente

Based on 34 publication(s) in Google Scholar

V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀=9.6 μM) in HEK-293 cells.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.46%
No. CAS: 1855871-76-9
Fòrmula: C₃₄H₃₈N₂O₄
Peso molecular:538.68

Almacenamiento:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

V-9302 Chemical Structure

No. CAS: 1855871-76-9

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (34)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

ASCT2

Ver todos los productos específicos de isoformas ASCT :

ASCT2

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	20.46 μM Compound: V9302	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 38217503]
C6	IC₅₀	9 μM Compound: 17	Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]
HEK293	IC₅₀	9.6 μM Compound: 17	Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]

In Vitro

V-9302 inhibits ASCT2-mediated glutamine uptake in human cells in a concentration-dependent fashion and exhibits a 100-fold improvement in potency over gamma-L-glutamyl-p-nitroanilide^[1].
Pharmacological blockade of ASCT2 with V-9302 results in attenuated cancer cell growth and proliferation, increases cell death, and increases oxidative stress^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

V-9302 (75 mg/kg; i.p.; daily fo 21 days) prevents tumor growth in both HCT-116 and HT29 xenograft models^[1].
The combination of CB-839 and V-9302 (30 mg/kg; i.p.; SNU398 and MHCC97H cells were grown as tumor xenografts in BALB/c nude mice; for 20 or 15 d, respectively) elicits a strong growth inhibition in both SNU398 and MHCC97H xenograft models, while single-drug treatment showed modest anti-tumor effects^[2].
V-9302 (50 mg/kg ; i.p.; daily for 5 days) displays markedly reduced tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-week old, female athymic nude mice (bearing HCT-116 (KRAS G13D) or HT29 (BRAF V600E) cell-line)^[1]
Dosage:

75 mg/kg
Administration:

Intraperitoneally; daily fo 21 days
Result:

Prevented tumor growth.

Chemical Information

No. CAS 1855871-76-9
Appearance Solid
Peso molecular 538.68
Fòrmula C₃₄H₃₈N₂O₄
Color White to yellow
SMILES

O=C(O)[C@@H](N)CCN(CC1=CC=CC=C1OCC2=CC=CC(C)=C2)CC3=CC=CC=C3OCC4=CC=CC(C)=C4
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (34)

All Cell Imaging/StainingIn Vivo Efficacy StudyOthersIHCBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nature

Ageing promotes metastasis via activation of the integrated stress response. [Abstract]

2026 Apr;652(8112):1339-1348. PMID: 41813904
Cell

A two-front nutrient supply environment fuels small intestinal physiology through differential regulation of nutrient absorption and host defense. [Abstract]

2024 Oct 31;187(22):6251-6271.e20. PMID: 39427662
Cell Metab

Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies. [Abstract]

2022 Dec 6;34(12):1999-2017.e10. PMID: 36395769
Nat Immunol

NaCl enhances CD8+ T cell effector functions in cancer immunotherapy. [Abstract]

2024 Oct;25(10):1845-1857. PMID: 39198631
Autophagy

PSAT1 inhibits mTORC1 activation by preventing Rag heterodimer formation in lung adenocarcinoma. [Abstract]

2025 Jul 23:1-16. PMID: 40702660
Cell Discov

ASCT2 palmitoylation regulated by JNK1-ZDHHC14 axis orchestrates glutamine metabolism and NSCLC progression. [Abstract]

2026 Feb 24;12(1):13. PMID: 41730846
Mol Cell

Mitochondrial glutamine import sustains electron transport chain integrity independently of glutaminolysis in cancer. [Abstract]

2026 Jan 8;86(1):150-165.e9. PMID: 41435838
J Nanobiotechnology

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer. [Abstract]

2022 May 6;20(1):216. PMID: 35524267
Adv Sci (Weinh)

Real-Time Tracking of ASCT2-Mediated Glutamine Uptake in Living Tumors With a Bioorthogonal Bioluminescent Probe. [Abstract]

2025 Aug 10:e07057. PMID: 40783801

V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 10:e07057. [Abstract]

V-9302 (50 μM, 35 min) suppressed the bioluminescent intensity of HCT116‐luc cells.

V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 10:e07057. [Abstract]

V-9302 (25 or 50 μM, 35 min) lowered the total photon flux induced by BL568 or AA201 in HCT116‐luc cells.

V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 10:e07057. [Abstract]

V-9302 (25 μM, 70 min) reduced intracellular AA201 levels in all three cell lines.
Adv Sci (Weinh)

Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib-Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency. [Abstract]

2025 Feb;12(6):e2411479. PMID: 39680480

V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb;12(6):e2411479. [Abstract]

V9302 (s.c., 30 mg kg⁻¹, 20 days) in combination with LL202 (s.c., 30 mg kg⁻¹, 20 days) inhibited tumor growth in the H1975OR xenograft model.

V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb;12(6):e2411479. [Abstract]

V9302 (s.c., 30 mg kg⁻¹, 20 days) in combination with LL202 (s.c., 30 mg kg⁻¹, 20 days) increased γH2AX expression level and the number of TUNEL‑positive cells in the H1975OR xenograft model.
Biomaterials

Targeting ROS-metabolism dual pathways to trigger PANoptosis by cobalt-vanadium oxides biomimetic nanocakes for tumor immunotherapy. [Abstract]

2025 Sep 17:326:123726. PMID: 40987137
J Control Release

Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. [Abstract]

2023 May:357:460-471. PMID: 37068523
Cell Death Dis

IL-17 promotes osteoclast-induced bone loss by regulating glutamine-dependent energy metabolism. [Abstract]

2024 Feb 5;15(2):111. PMID: 38316760
Nano Today

2025 Apr.
Proc Natl Acad Sci U S A

Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer. [Abstract]

2024 Mar 26;121(13):e2319429121. PMID: 38513095
Int J Biol Macromol

Glutamine modified lipid nanoparticles loaded with GPX4 siRNA for cervical cancer targeting. [Abstract]

2026 Jan:336:149419. PMID: 41338505
Pharmaceutics

Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. [Abstract]

2024 Jun 29;16(7):877. PMID: 39065573
Biochem Pharmacol

SLC1A5 mediates myocardial damage after myocardial infarction by triggering cardiomyocyte ferroptosis. [Abstract]

2025 Sep:239:117047. PMID: 40490039
Biochem Pharmacol

Glutamine transporter inhibitor enhances the sensitivity of NSCLC to trametinib through GSDME-dependent pyroptosis. [Abstract]

2025 Mar:233:116796. PMID: 39923858
J Gastroenterol

Inhibition of integrin α3 suppresses gastric cancer progression via STAT3-mediated regulation of SLC1A5-dependent glutamine uptake. [Abstract]

2025 Oct 8. PMID: 41060436
Front Pharmacol

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib. [Abstract]

2021 May 14:12:671328. PMID: 34054543
Cancers (Basel)

SNAT1 (SLC38A1) Is Not the Main Glutamine Transporter in Melanoma, but Controls Metabolism via Glutamine-Dependent Activation of P62 (SQSTM1)/cMYC-Axis. [Abstract]

2026 Mar 25;18(7):1068. PMID: 41976291
Biomedicines

Targeting the Glutamine Transporter SLC1A5 Enhances Sensitivity of Acute Myeloid Leukemia to MLN4924. [Abstract]

2026 Mar 14;14(3):667. PMID: 41898313
FASEB J

Trained Immunity Induced by Oxidized Low-Density Lipoprotein Is Dependent on Glutaminolysis. [Abstract]

2025 Jul 15;39(13):e70774. PMID: 40577101
J Virol

African swine fever virus hijacks host pyrimidine metabolism to promote viral replication. [Abstract]

2025 Nov 25;99(11):e0098525. PMID: 41171159
J Biol Chem

Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. [Abstract]

2022 Apr;298(4):101753. PMID: 35189139
Magn Reson Imaging

MRI measurement of alanine uptake in a mouse xenograft model of U-87 MG glioblastoma. [Abstract]

2022 Nov:93:189-194. PMID: 36029935
bioRxiv

2026 Mar 5.
Npj Imaging

Imaging the uptake and metabolism of glutamine in prostate tumor models using CEST MRI. [Abstract]

2025 Aug 1;3(1):34. PMID: 40750673
bioRxiv

Surface avidity of anionic polypeptide coatings target nanoparticles to cancer-associated amino acid transporters. [Abstract]

2025 Jul 31:2025.07.28.667320. PMID: 40766676
University of Regensburg

2024 Jul 18.
bioRxiv

2024 July 05.
University of Maryland

2024.
Research Square Print

2023 Jan 31.

Solvente y solubilidad

In Vitro:

DMSO : 25 mg/mL (46.41 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8564 mL

9.2819 mL

18.5639 mL

5 mM

0.3713 mL

1.8564 mL

3.7128 mL

10 mM

0.1856 mL

0.9282 mL

1.8564 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1 mg/mL (1.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202. [Content Brief]

[2]. Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5. [Content Brief]

[3]. Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8564 mL	9.2819 mL	18.5639 mL	46.4097 mL
	5 mM	0.3713 mL	1.8564 mL	3.7128 mL	9.2819 mL
	10 mM	0.1856 mL	0.9282 mL	1.8564 mL	4.6410 mL
	15 mM	0.1238 mL	0.6188 mL	1.2376 mL	3.0940 mL
	20 mM	0.0928 mL	0.4641 mL	0.9282 mL	2.3205 mL
	25 mM	0.0743 mL	0.3713 mL	0.7426 mL	1.8564 mL
	30 mM	0.0619 mL	0.3094 mL	0.6188 mL	1.5470 mL
	40 mM	0.0464 mL	0.2320 mL	0.4641 mL	1.1602 mL

Keywords

V-9302

34 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

V-9302

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) V-9302

Ver todos los productos específicos de isoformas ASCT

Actividad biológica

Chemical Information

Publications (34)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

V-9302

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) V-9302

Ver todos los productos específicos de isoformas ASCT

Actividad biológica

Chemical Information

Publications (34)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

V-9302 Related Classifications

HY-112683 Related Classifications